- Home
- CRTO vs MLTX Comparison
CRTO vs MLTX Comparison
Compare CRTO & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRTO | MLTX |
|---|---|---|
| Founded | 2005 | 2021 |
| Country | France | Switzerland |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 904.7M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRTO | MLTX |
|---|---|---|
| Price | $19.74 | $13.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $38.67 | $36.33 |
| AVG Volume (30 Days) | 447.8K | ★ 2.2M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.79 | N/A |
| EPS | ★ 3.00 | N/A |
| Revenue | ★ $1,956,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.84 | N/A |
| P/E Ratio | $6.57 | ★ N/A |
| Revenue Growth | ★ 0.53 | N/A |
| 52 Week Low | $19.15 | $5.95 |
| 52 Week High | $47.27 | $62.75 |
Technical Indicators
Market Signals| Indicator | CRTO | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.12 | 51.96 |
| Support Level | $19.15 | $12.43 |
| Resistance Level | $20.22 | $13.99 |
| Average True Range (ATR) | 0.78 | 0.73 |
| MACD | -0.16 | 0.75 |
| Stochastic Oscillator | 15.06 | 95.68 |
Price Performance
Historical ComparisonAbout CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.